Mitigation of in-hospital risk of coronavirus disease 2019: Experience from a haematology-oncology and stem cell transplant setting

0Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

Abstract

Background. Coronavirus disease 2019 (Covid-19) was first described in December 2019 and has evolved into an ongoing global pandemic. Cancer patients on chemotherapy are immunocompromised and are at the highest risk of Covid-19-related complications. We describe our experience with the management of haematology-oncology and stem cell transplant (SCT) patients receiving curative chemotherapy in a hospital with a high influx of Covid-19 patients. Methods. We did a prospective observational study at a 99-bedded cancer centre of a tertiary care teaching hospital from April 2020 to September 2020. Preventive measures taken were categorized as follows: (i) staff: screening, mandatory use of personal protective equipment (PPE), risk stratification of potential exposure and testing and isolation as needed; (ii) patients: mandatory viral polymerase chain reaction testing, segregation of positive and untested patients and testing of family members; and (iii) environment: mandatory regular cleaning, visitor restriction, telemedicine services and reassignment of priority to clinic visits. Treatment of the underlying conditions was continued with added precautions. Results. A total of 54 patients were included in the analysis, including 48 with haematological malignancies and 6 for stem cell therapy. Preventive measures were universally applied, and chemotherapy with a curative intent was initiated as per protocol. Three patients were detected to have Covid-19 infection before admission and one after the institution of chemotherapy. Nine patients died after the first cycle of chemotherapy, 2 due to severe Covid-19-related illness and 7 due to complications of chemotherapy or disease progression. Conclusions. In the wake of the Covid-19 pandemic, treatment for haematological malignancies must continue while balancing the risk of Covid-19 infections. Our report emphasizes the effectiveness of measures such as hand hygiene, social isolation, patient segregation, use of masks and PPE and universal pre-treatment testing for Covid-19 in reducing the risk of infection in a high-risk clinical setting.

References Powered by Scopus

Clinical characteristics of coronavirus disease 2019 in China

21584Citations
N/AReaders
Get full text

A novel coronavirus from patients with pneumonia in China, 2019

20172Citations
N/AReaders
Get full text

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

13514Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Singh, S., Paul, D., Jain, K., & Singh, J. (2021, January 1). Mitigation of in-hospital risk of coronavirus disease 2019: Experience from a haematology-oncology and stem cell transplant setting. National Medical Journal of India. Wolters Kluwer Medknow Publications. https://doi.org/10.4103/0970-258X.315901

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

76%

Lecturer / Post doc 2

10%

Researcher 2

10%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

45%

Nursing and Health Professions 11

38%

Pharmacology, Toxicology and Pharmaceut... 3

10%

Social Sciences 2

7%

Save time finding and organizing research with Mendeley

Sign up for free